In preclinical studies, STINGVAX activated dendritic cells (DCs), enhanced tumor-infiltrating lymphocytes (TILS) and in combination with PD-1 blockade, induced tumor regression of established tumors [56]. This evidence concerns the gene PDCD1 and neoplasm.